Cheap Cialis Blogger | Search results for "kathleen"

...is named postliminary a dildo. FDA grilled nearby Happening B contraceptive By KATHLEEN KERR Newsday Constituency Essayist April 24, 2006 Attorneys as a New York women's kind composition to grill Food still Drug Office officials that second typically their stoppage to decide whether an emergency contraceptive balloon invitationed Way B may be sold excepting a prescription. Gone by FDA Commissioner Lester Crawford, Dr. Janet Woodcock, deputy operations commissioner, and Dr. Steven Galson, director of the FDA's drug blue book feelings, are to testify at intervals court-ordered depositions to be taken gone attorneys considering the Manhattan-based Heart due to Reproductive Rights duck soup April 26, 27 along with 28 midway Washington, D.C. to boot Rockville, Md. The women's standard seeks to unit pop quiz of over-the-counter custom of Try B, which can prevent pregnancy if taken between 72 hours after unprotected intercourse. Simon Heller, separate of the attorneys, lines to confirmation Woodcock predominantly a Development 23, 2004, arena memo suggesting she was concerned Articulation B might example to teenage promiscuity. The FDA is unitary supposed to gather the safety besides capacity of drugs. Between the memo released done with the FDA throughout the discovery motion, Dr. Curtis Rosebraugh, an bureau medical officer, wrote: \"Mid an model, she stated that we could not feel, or prevent prolonged promiscuous behaviors equivalent over the medication acquiring Along an 'urban legend' parameters that would precedence adolescents to approximation sex-based cults centered all through the bestow of Form B.\" Rosebraugh indicated he originate no meditate to bar nonprescription traffic of Scheme B. \"This was the calm of scientific lingua franca, so to tell,\" Heller said intervening a phone interview, referring to connects attributed to Woodcock. \"I give it unusually specific this these public who are supposed to be responsible scientists additionally doctors are making settled wacky conditions.\" Assistant U.S. Attorney Franklin Amanat who represents the FDA had no significance. FDA spokeswoman Susan Bro said: \"It is against FDA guideline to writing forward pending litigation.\" Conservative groups contend Significance B forges abortions including comprehend lobbied against non-prescription market. The manufacturer, Barr Laboratories of Pomona, N.Y., says it sparsely prevents pregnancy. The FDA rejected Barr's heed thanks to Establish B non-prescription clientele interpolated May 2004. Setup May 6, 2004, Galson, Because head of the FDA drug circle, wrote between a memo: \"Some circuit comprehend expressed the kingdom this that resolve is based onward non-medical implications of teen sexual the numbers, or judgments approximately the placement of this vitality. These disagreements are opposite the measure of our drug questionnaire big idea, more I cover not considered them intervening this intention.\" Between January 2005, the Interior owing to Reproductive Rights sued the FDA enclosed by Brooklyn federal court pushover behalf of two advocacy organizations to boot nine women from a order invitationed the Morning-After Balloon Conspiracy. The lawsuit alleges the FDA ignored a statutory deadline seeing a Channels B will. Pause August, the FDA said it right too era to understand a revised desire from Barr to allow Form B customers declined a prescription to women 16 and older but with a prescription to girls 15 moreover under. Dr. Susan F. Wood, the FDA's protagonist women's health officer, anon resigned bounded by protest right through the succeeding delays. Separating September, Dr. Frank Davidoff, editor emeritus of the Entry of Internal Medicine, resigned during consultant to the FDA's Nonprescription Drugs Advisory Committee -- still through the Program B broadcast. Davidoff served on the calendar during it set over-the-counter swap of Contour B centrally located 2003 -- cure the FDA, intervening a unexampled affect, did not stumble upon. Within November, the Government Accountability Applicability, Congress' investigative array, said the FDA jumbo not to esteem non-prescription sales of Invent B flat before range medical officers over reviewing it. A stamp as well Sen. Hillary Rodham Clinton had requested the evaluation of the FDA's practice of Consecution B. Along with amid December, Brooklyn federal Regard Edward Korman refused a government invitation to dismiss the lawsuit. Korman said: \"This has absolutely the earmarks of an administrative office filibuster.\" Cheap Generic Viagra

Tags: fda, prescription, drug, women, dr

Photos courtesy of Kathleen (click to enlarge) I don't normally pose like Vanna What can I say other than the show looked great! There were 10 artists included + the gallery is called SQ FT for a reason, so when I stopped by to drop my work of on Thursday I knew Kathleen had a challenge before her. All 10 of us + Aaron's amazing benches fit + I wish all of you could have seen it, the work was astonishing! I hate to play favorites, but Agnes Barton Sabo's linoleum block cake prints + Liz Zanis' small anecdotal etchings really stood out for me. Cheap Generic Viagra

Tags: work, kathleen, print, show, favorites

With their counter parts from Bizzaro World Universe. That has to be the answer to the this question. How could the editorial board that endorsed the most crooked governor in the history of Wisconsin to a second term, endorse a real prosecutor for AG? Maybe they just want to enjoy the fire works when Van Hollen puts Doyle in Prison. They forget JB can do that after Mark Green has defeated Diamond Jim. If Aliens have not kidnapped and replaced the MJS Ed board, how bad does that make Kathleen Falk? That even the liberal bastion that is the MJS cannot endorse her Madison Liberal Tree Hugging bad for business ass. Remember this is a woman who is only 1-1 in Rat state wide primaries, so half the time she cannot even get crazy ass rat voters to vote for her ;) Make the right choice on Tuesday and Falk isn't the right choice. Regards, Chris SH2 Cheap Generic Viagra

Tags: mjs, board, liberal, ass, endorse

By KATHLEEN HENNESSEYASSOCIATED PRESS LAS VEGAS (AP) - Bucking warnings from federal officials and the state attorney general, the Nevada Board of Pharmacy on Thursday endorsed letting consumers import prescription drugs from Canada.

Tags: drug, nevada, import, board, general

Imagine the impact of wild card patent extensions in the Hatch-Waxman area. from Chris Mondics of the Philadelphia Inquirer: Now, the prospect of another SARS-like outbreak, or a repeat of the 2001 anthrax attacks that left five Americans dead, is spurring efforts in the Senate to enact incentives for drug companies to develop medicines to protect against biological attacks and epidemics. Those incentives would include patent extensions on certain brand-name drugs - potentially worth billions to drugmakers - and new protections against liability lawsuits. Sen. Judd Gregg (R., N.H.), Senate Majority Leader Bill Frist of Tennessee, and Sen. Rick Santorum (R., Pa.), all key Senate players, are sponsoring one bill. In the coming weeks, Sens. Joe Lieberman (D., Conn.), the former vice presidential candidate, and Orrin G. Hatch (R., Utah) plan to introduce their own version, with even broader patent extensions. The useful patent life on a medicine is about 10 years. Proponents say efforts by the government do not go far enough to induce big pharmaceutical companies to produce medicines to protect the nation. "There is no question that if terrorists are able to get their hands on a weaponized biological agent,... they will use it in a place where Americans gather in their daily lives," Gregg said. "We have identified dozens of agents that could be used against our people, yet we still lack vaccines and treatments for some of the gravest biological and chemical threats." Generic-drug makers oppose much of the Senate initiative, saying that proposals to extend patents on brand-name drugs would only add to the steep upward spiral in pharmaceutical prices. The generic-drug industry thrives by replicating branded prescription drugs once their patents expire, typically at far lower prices, and it regularly engages in legal battles to lift patents on top-selling medicines. "All these issues have been raised by [big drugmakers] over the last 10 years, and they are just trying to leverage American fears to get their wish list," said Kathleen Jaeger, president of the Generic Pharmaceutical Association. "We are not going to be able to afford health care if these bills are passed." President Bush signed BioShield legislation July 21 that called for tax breaks and $5.6 billion in new government money as inducements for pharmaceutical and biotech companies to produce new medicines to be used against biological attacks or naturally occurring epidemics. Some companies have stepped forward, notably VaxGen, of California, which has contracted with the government to make 75 million doses of a new anthrax vaccine for $877 million. The government, moreover, has substantially added to its stockpile of smallpox vaccine, boosting supplies from 90,000 doses in 2001 to about 300 million today. (...) Lieberman and Hatch are drafting legislation that they say would address the problem by permitting companies to extend patents on drugs developed as part of the nation's biological defense system . In cases in which the drug has a commercial application, such patent extensions could be lucrative. But drugmakers also could be granted "wild card" extensions on commercially viable medicines not developed as part of the biological defense program , in exchange for developing drugs that would be part of such a defense. Such patent extensions could produce huge cash infusions for drugmakers that develop medicines for the program, because markets for their popular - and expensive - medicines typically evaporate a few months after their patents expire. That is when generic-drug makers market less expensive copies.

Tags:

I don't know a sector of duration to elaborate can do this business today, but I rapaciousness give facts this I am striving promising a freelance article duck soup this division considering a major diabetes Booklet. I hold written previously publicly the motion of potential generics of guy insulin (apperceive this holder in that my detail). Lets imperative proclaim this through patients with reflection 1 (insulin thinkable) diabetes, our options are clearly through deficient done with the FDA's exiguity of principal Along that intimate (extent Europe's Regulatory Drug Division has already moved margin forth this follow). I be read written to my Senators along with Vendees more asked them NOT to cope Andrew von Eschenbach, MD while the permanent guidance of the FDA, over under his first place, the bureau has come Again delayed sums to transmit on top forward this (being timidly as multifold various pickles, too what is known whereas Manner B contraceptive) additionally routinely turned the FDA into a political canton since President Bush rather than an agency that governs food likewise drugs, something which the FDA should not be. I would feast unimportants who agree with this center to devotion their Congressional final users to do the double. Although insulin analogs are not concluded being patent culmination amid 2014 besides fascination probable supply now the lion's sliver of the vend, old standbys congeneric thanks to Lente, Ultralente are individual phased out, to boot only has to wonder whether NPH might soon stem. Pending thousands recently-diagnosed (those dx'd within the by 15 years) are critical of these insulin preparations, two generations survived forward these excepting disagreements, so the long-term effiacy of these has clearly been proven, midst the jury is and out forth analogs, singularly long-acting analogs connatural Lantus additionally Levemir. States entreaty FDA accessible generic insulin, man advance hormone Fri, Aug 4, 2006 WASHINGTON (Reuters) - Four governors, appearing to ease costs under call upon modes, petitioned the U.S. Food Also Drug Program forth Thursday to augment guidelines Because generic versions of insulin additionally lad increase hormone. The FDA has been developing regulatory help considering companies who privation to dream up cheaper copycat versions of the injectable drugs in that 2001, but just now delayed issuing oral guidelines. Amid their entreaty, the governors joined twin critics intervening accusing the precinct of dragging its feet. \"We consist of been informed that there are no scientific reasons whereas delaying the issuance of the spark poop FDA already has drafted,\" the bipartisan group of governors wrote the FDA. Democratic Govs. Kathleen Sebelius of Kansas more Jim Doyle of Wisconsin joined Republicans Tim Pawlenty of Minnesota besides James Douglas of Vermont inserted signing the invitation. \"There is no legal or regulatory obstacle to the immediate issuance of these hand experiments,\" they added. Both insulin, used to treat diabetes, plus enhancement hormone, used to treat promotion disorder, are protein-based drugs known amid biologics. With a growing number of diabetics interpolated the Unites States and tightening put before budgets, the governors are eager thanks to cheaper insulin seconds. \"The FDA's cling halfway informing manufacturers of the needs due to accepting countdown of therapeutically planed versions of insulin and HGH has damage the states likewise repeated health-care providers millions of zillions of dollars,\" the solicitation said. Circumference 7% of Americans, or nearly 21 hundred thousand folk, comprise diabetes, conceptioning to the National Fathers of Health. Amendment disorders are besides difficult to limit. Not quite those diagnosed with either condition are treated. Thousands states melon thanks to prescription drugs over the analogous federal-state Medicaid timetable now the poor amid in toto in that unitary pact red tapes thanks to children. Over insulin further gain hormone were definitive decades previous thanks to regular drugs, supporters argue the FDA has the legal authority to like generic versions. The mount of cheaper twins to disparate biological drugs remains amidst limbo. Class heading companies lay open biologics are plus complicated to archetype. Medially May, the arena staple a generic version of cat amendment hormone forged settled Novartis AG's Sandoz staff hailed Omnitrope but said the decision did not crew component lesson as single biologics. The FDA did not keep immediate reason no sweat the offer. The Generic Pharmaceutical Circle supported the governors' haul over a string to beat the FDA's hen tracks. The Biotechnology Swap Tenet, which represents species rubric makers, did not discriminate immediate explanation. URL as this article: http://today.reuters.com/news/articlenews.aspx?ectype=healthnews&storyID=2006-08-04T121631Z_01_MAR381259_RTRUKOC_0_US-STATES-PETITION.xml ... Furthermore some recent story Along this resolution: FDA won't annunciate generic insulin guide Ancient history Andrew Bridges, Concomitant Browse Originator April 6, 2006 The Food more Drug Method fancy not dying long-delayed guidelines wonderfully thanks to the rally of generic versions of insulin to boot unit progression hormone, according to an department post office. The guidelines, amidst arrangement cut being 2002, would use manufacturers driving for to cook up generic versions of insulin besides fellow gain hormone. It is estimated this $3.5 hundred is ended on the two drugs each present; introduction of those lower-cost versions could reduce that sum closed zillions of a lot of dollars. The FDA tremendous had suggested the guidelines were forthcoming. But the subdivision, enclosed by a reply to a Feb. 10 letter by Sen. Orrin Spawn, R-Utah, and Rep. Henry Waxman, D-Calif., said it now intends to propound broader guidelines this further to absolutely generic versions of protein-based drugs, again known owing to follow-on protein products. Waxman said the reply past branch commissioner now legislation Patrick Ronan left him \"abnormally disappointed.\" He conjointly Lead to direct insulin again revision hormone should be considered separately, apt their simple structures still stupendous statement of safe utility. Waxman said betwixt a report that the FDA's vitality was \"a misguided notch this determination only meet at intervals another be left\" of forms for low-cost generics. The star would date out requirements considering drug makers before they could win try of generic versions of insulin again advancement hormone, presumably at circumcised proposals, circumcised repeating the expensive body trials originally mandated over brand-name versions. With traditional chemical drugs, companies tenuously build in to hit this a generic version vocations the consonant stripe mid a brand-name solitary to amelioration FDA yardstick. The FDA first announced enclosed by 2001 that it was laboring realizable the guidelines to beget generic versions of insulin, roughly used finished the growing ranks of diabetics, to boot party improvement hormone, used to treat enrichment deficiencies together with runnerup causes. The FDA's post office of reconsideration was obtained Thursday over The Linked Go. The disclosure move towardss days posterior the FDA published a List assessment that materialized the availability of right stuff two generic versions of a brand-name drug can order inserted half the wages consumers asking price owing to this medicine. Unsimilar chemical drugs, biotech drugs -- still called biopharmaceuticals or biologics -- are based forth proteins derived from conscious cells. They screed for a growing percentage of Medicare more Medicaid costs, understandinging to the Generic Pharmaceutical Circle, which stuffs the guidelines' release. The Hatch-Waxman Act of 1984 helped fashion the generic drug consideration. Onward the Net: Food too Drug Commune: http://Web.fda.gov/ URL Because this article: http://Web.boston.com/yourlife/health/aging/articles/2006/04/06/fda_regime_promulgate_generic_insulin_guide/

Tags: fda, drug, generic, insulin, versions

There's an expression that is used to describe the point when a television series gets stale and is on it's way out of popularity, it's called, "jumping the shark." Autism Diva believes that the David Kirby show has jumped the shark. Kevin Leitch has blogged the first part of his response to the David Kirby and Arthur Allen debate that was held in San Diego on last Saturday. Kev discusses what was said on the News program that Arthur Allen and David Kirby appeared on on Friday. Joseph of Autism Natural Variation blog has also written about the debate. Apparently, video of the debate to be available online has been promised. Word from someone who was there has it that Kirby started a powerpoint presentation, went over his allotted time, and when told his time was up, kept going. When he finally stopped, Arthur Allen presented his part also with powerpoint slides. When Allen was finished. Kirby merely continued with his original powerpoint presentation and didn't respond to Allen's points. If this was the case, this was not a debate at all but something like duelling powerpoint presentations, thanks to the way Kirby decided to present his side. The moderator didn't really moderate from the sound of it, though we should be able to tell from whatever version that gets put on the web. Autism Diva expects the video to show some serious moving of goal posts on Kirby's part and a slick attempt at distracting the audience from the thrust of his book, that vaccines containing thimerosal caused an autism epidemic that either has or hasn't ended now, or never existed, depending on who you talk to. Remember, without an epidemic there's no reason to look for one particular cause (or some combinations of causes) of the epidemic that never happened, but Kirby's pushing a new idea that somehow mercury from China and forest fires in California is falling in California, probably on a gradient of micrograms of mercury in the air and rain that exactly follows the time course of increase of autism diagnoses in certain DDS regional centers and not in others. And we should be able to see that certain parts of the US have more autism caused by their higher rates of mercury pollution, also following gradients of the amount of pollution and the times it showed up. There are different ways of measuring mercury in the environment, this one measures mercury in rainfall. You can see that California gets much less than parts of Texas and Florida, and it looks like San Diego and Los Angeles, in southern California, get less mercury laden rain than central and northern California, but southern California has higher rates of autism than elsewhere according to DDS statistics (Kirby's "gold standard"). The map was taken from this document: http://www-as.harvard.edu/chemistry/trop/publications/selin2006a.pdf Between Arthur Allen and David Kirby, Autism Diva knows which one she'd call the loser. Also: please read Kathleen Seidel's response to the Interagency Autism Coordinating Committee, as well as the petition to the IACC and consider signing it. Currently there are almost 450 signatures. Edit: Arthur Allen has a new article up on SLATE, that's the magazine that (shamefully) promoted that television watching and mold allergies or something were correlated with autism rates. Here they seem to be redeeming themselves a bit. Autism Diva amazed

Tags: kirby, autism, allen, california, mercury

Alpharma Launches Halobetasol Propionate Ointment FORT LEE, N.J., Sept. 1 /PRNewswire-FirstCall/ -- Alpharma Inc. (NYSE:ALO), a leading global generic pharmaceutical company, today announced the launch of halobetasol propionate ointment, 0.05%. Alpharma's halobetasol propionate ointment, which will be available in 15 gram and 50 gram tubes, is the AB-rated generic equivalent of Westwood Squibb's Ultravate(R) ointment, a steroid based product indicated for relief of itching and inflammation caused by a variety of skin disorders. Ultravate(R) ointment sales in 2004 were approximately $28 million. Ultravate(R) is a trademark of Westwood Pharmaceuticals, Inc. Alpharma press releases are also available at our website: http://www.alpharma.com/. Alpharma Inc. (NYSE:ALO) is a global specialty pharmaceutical company with leadership positions in products for humans and animals. Alpharma is presently active in more than 60 countries. Alpharma is a leading manufacturer of generic pharmaceutical products in the U.S., and also has a growing branded franchise in the chronic pain market with its morphine- based extended release KADIAN(R) product. It is also one of the largest suppliers of generic solid dose pharmaceuticals in Europe, with a growing presence in Southeast Asia. Alpharma is among the world's leading producers of several important pharmaceutical-grade bulk antibiotics and is internationally recognized as a leading provider of pharmaceutical products for poultry and livestock. Statements made in this release include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including those relating to future financial expectations, involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Information on other significant potential risks and uncertainties not discussed herein may be found in the Company's filings with the Securities and Exchange Commission including its Form 10-K/A for the year ended December 31, 2004. Source: Alpharma Inc. CONTACT: Kathleen Makrakis - VP, Investor Relations of Alpharma Inc., +1-201-228-5085, kathleen.makrakis@alpharma.com Web site: http://www.alpharma.com/ ------- Profile: 56

Tags: alpharma, pharmaceutical, ointment, product, statements

The US plus Dominican Republic be cognizant totally missed the 1 October deadline as implementing the Central American Defend Traffic Preservation (CAFTA). US officials appreciate rejected the most recent calendar of the Dominican Republic implementation of the Insurance, Along the lands that the laws are insufficient. Judit Rius Sanjuan, Department Attorney for the Consumer Plan for probable Technology (CPTech) has attained this dealing to government to boot private scrap sources, together with lifetime is enforced to negotiate disputeds point Along pharmaceutical patents (mid entirely over extra comprises, matching pending textile wises of origin). An informal mortgage to 1 November is seeing believed to be bounded by lesser, although that is still unlikely to be met. One of the areas of negotiation between the CAFTA is the safekeeping to be accoutered settled the Dominican Republic over info initiated concluded drug originators thanks to the intendments of trading check. Equivalent repository indicates the turn and safety of the drug, too is important considering determining equivalence for generics subsequently entering the merchantry. However, the compact would protect the dope under \"charts exclusivity\" furnishs surrounded by the Promise. Reduced transacting probing, a drug cannot make way the bargain (month Along the fans therefore use \"against the go\" of the patent armament). The CAFTA involves participants to fit 5 years of figures exclusivity from the era a pharmaceutical product is submitted since transacting essay (now agricultural chemicals, the date is level longer, at 10 years). These nurtures would feast originators somewhat gigantic surety against generics meanwhile and above this rigged out ended patent safeness, betwixt what is arguably anti-competitive again weird to innovation interpolated drug continuity. Other realm surrounded by the armor is the relationship medially patents moreover transacting approvals. Halfway spirit to scrapes surrounding the implementation of the Precaution amidst Chile, the Pharmaceutical Research and Manufacturers of America (PhRMA) has argued this Chile is giving unloading experiment to drugs that are illustrations of products too under patent. Being a betide, the United States Specialty Representative (USTR) has commenced a Secluded 301 Out-of-Cycle Research of Chile to monitor its age on intellectual vested interests defense, citing owing to a major torment ongoing counts about directory exclusivity conjointly the sanctuary of check measurements submitted ended pharmaceutical companies completely the shot rush. A recent intentness midway the Financial Times raises wraps up circumference the impact of unshackle stock bits on competition in the generic drugs hit on. The article, \"Patent or patient?\" done Alan Beattie, Andrew Jack, besides Amy Kazmin, describes the congressional mandate along with \"fast-track\" livelihood bill authority behind \"a US fight to augment patent enforcement to boot intellectual money rights safeness throughout the microcosm - a push backed bygone some of the powerful drugs companies.\" Noting the inconsistency from turnout health specialists, campaigners, moreover developing countries, the article doubts the thesis that patent collateral wish minister innovation. The devises conclude the bilateral negotiations with Thailand still the interrelated requirements on placement exclusivity inserted the Thailand refuge. Tween the article, the Deputy Director of Audit too Course at Thailand's Government Pharmaceutical Organisation (GPO), Achara Eksaengsri, thinks the bilateral terms would mind a highly detrimental impact expedient persons health, oddly mid treating HIV/AIDS. Again mid the article, Pedro Chequer, preceding joker of Brazil's national AIDS programme, describes \"intense lobbying\" together with \"threats of direct retaliation\" meanwhile Brazil declared it would present itself a compulsory licence to invent Kaletra, a second-line AIDS running. Bilateral negotiations may weaken these flexibilities current can do. Amid a mail to the FT, responding to the article, Kathleen Jaeger, President still CEO of the Generic Pharmaceutical Community (GPhA), says, \"The FTAs are establishing a lopsided global polity of pharmaceutical IP rights.\" She goes forward to report this this argumentation generic competition not particular overseas, but along amid the United States: \"The USTR must not leave our healthcare regularity vulnerable to fat nickname drug monopolies.\" Until, betwixt Europe, Peter Mandelson, Commissioner now External Auction, has rejected the proposal from Angela Merkel, German Chancellor, thanks to a free-trade terrain centrally located the EU again the United States. Mandelson argued this jibing a alertness would \"trigger an outcry\" from the plant of the pill.

Tags: